alexa Hepatic Stellate Cells as a Target for the Treatment of

Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

To read the full article Peer-reviewed Article PDF image


Liver fibrosis as the final common end stage of most chronic liver diseases is triggered by chronic liver injury caused by various etiologies including viral infection, cholestasis, metabolic diseases and alcohol abuse. It is reversible wound-healing response characterized by the accumulation of extracellular matrix proteins (ECM) including collagen. Hepatic stellate cells (HSCs) are the major source of extracellular matrix components and are the key mediators of fibrogenesis. Hepatic stellate cells are definitely involved in the pathogenesis of various liver pathologies, besides the well know key role in fibrosis and extracellular matrix remodelling. Potent drugs may not be effective enough in the treatment of liver fibrosis. The inflammatory cytokines produced by kupffer cells, the liver resident macrophage, aggravate liver fibrosis. Transforming growth factor β1 (TGF- β1) is also activator of HSCs. Liver fibrosis is a serious healthcare problem with high morbidity and motility. It is the result of wound healing responses to repeated liver injury irrespective of etiology. With the development of the diseases, excessive extracellular matrix (ECM) components are deposited in the liver, leading to portal hypertension, cirrhosis or hepatocellular carcinoma .Normally HSCs are quiescent in nature but when liver have any injury they get activated and releases extracellular matrix proteins. The review describes the use of HSCs, transforming growth factor β1 for therapeutic purposes in liver fibrosis.


Recommended Journals

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version